JP2016505561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505561A5 JP2016505561A5 JP2015546448A JP2015546448A JP2016505561A5 JP 2016505561 A5 JP2016505561 A5 JP 2016505561A5 JP 2015546448 A JP2015546448 A JP 2015546448A JP 2015546448 A JP2015546448 A JP 2015546448A JP 2016505561 A5 JP2016505561 A5 JP 2016505561A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- subject
- highly active
- antiretroviral therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011225 antiretroviral therapy Methods 0.000 claims description 25
- 229920001393 Crofelemer Polymers 0.000 claims description 15
- 229940047615 crofelemer Drugs 0.000 claims description 15
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 claims description 15
- 206010012735 Diarrhoea Diseases 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 12
- 229960004556 tenofovir Drugs 0.000 claims description 9
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 9
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 8
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 8
- 229960000366 emtricitabine Drugs 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 229960000311 ritonavir Drugs 0.000 claims description 8
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 8
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical group N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 7
- 229960004525 lopinavir Drugs 0.000 claims description 7
- 229960004748 abacavir Drugs 0.000 claims description 6
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 6
- 229960001627 lamivudine Drugs 0.000 claims description 6
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 6
- 208000031886 HIV Infections Diseases 0.000 claims description 5
- 208000037357 HIV infectious disease Diseases 0.000 claims description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 5
- 208000004998 Abdominal Pain Diseases 0.000 claims description 4
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229940120922 lopinavir and ritonavir Drugs 0.000 claims description 4
- 230000035699 permeability Effects 0.000 claims description 4
- 229960002555 zidovudine Drugs 0.000 claims description 4
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 4
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Chemical group O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003804 efavirenz Drugs 0.000 claims description 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical group C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 3
- 230000033001 locomotion Effects 0.000 claims description 3
- LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 claims description 2
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims description 2
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims description 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 208000034347 Faecal incontinence Diseases 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 2
- 206010000059 abdominal discomfort Diseases 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 229960003277 atazanavir Drugs 0.000 claims description 2
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 2
- 229960005107 darunavir Drugs 0.000 claims description 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims description 2
- 230000006866 deterioration Effects 0.000 claims description 2
- 229960002656 didanosine Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 206010016766 flatulence Diseases 0.000 claims description 2
- 208000014617 hemorrhoid Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229960000884 nelfinavir Drugs 0.000 claims description 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000019206 urinary tract infection Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- -1 et Mutorishitabin Chemical compound 0.000 claims 1
- 230000010006 flight Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 41
- 150000001875 compounds Chemical class 0.000 description 16
- 230000002411 adverse Effects 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734901P | 2012-12-07 | 2012-12-07 | |
| US61/734,901 | 2012-12-07 | ||
| PCT/US2013/032395 WO2014088629A1 (en) | 2012-12-07 | 2013-03-15 | Methods and compositions for treating hiv-associated diarrhea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016505561A JP2016505561A (ja) | 2016-02-25 |
| JP2016505561A5 true JP2016505561A5 (enExample) | 2016-04-28 |
Family
ID=50881628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015546448A Pending JP2016505561A (ja) | 2012-12-07 | 2013-03-15 | Ｈｉｖ関連下痢を治療する方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140163096A1 (enExample) |
| EP (1) | EP2928560A4 (enExample) |
| JP (1) | JP2016505561A (enExample) |
| CA (1) | CA2893070A1 (enExample) |
| MX (1) | MX2015007065A (enExample) |
| WO (1) | WO2014088629A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070254050A1 (en) | 2006-05-01 | 2007-11-01 | Quart Barry D | Method for treatment of diarrhea-predominant irritable bowel syndrome |
| PL2529626T3 (pl) | 2006-05-01 | 2018-04-30 | Napo Pharmaceuticals, Inc. | Kompozycje i sposoby leczenia lub zapobiegania nowotworowi okrężnicy |
| SG195538A1 (en) | 2006-05-01 | 2013-12-30 | Napo Pharmaceuticals Inc | Method for treatment of constipation-predominant irritable bowel syndrome |
| EP2632550B1 (en) | 2010-10-31 | 2017-05-03 | Napo Pharmaceuticals, Inc. | Methods and compositions for treating hiv-associated diarrhea |
| WO2015155673A1 (en) * | 2014-04-08 | 2015-10-15 | Teva Pharmaceutical Industries Ltd | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir |
| US10380937B2 (en) | 2015-08-26 | 2019-08-13 | Apple Inc. | Multi-zoned variable VCOM control |
| US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210659A1 (en) * | 2002-01-24 | 2003-09-02 | Sangstat Medical Corporation | Combination therapy for treatment of hiv infection |
| JP2009524585A (ja) * | 2005-12-15 | 2009-07-02 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ウイルス感染を処置するためのジアリールウレア |
| US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
| EP2632550B1 (en) * | 2010-10-31 | 2017-05-03 | Napo Pharmaceuticals, Inc. | Methods and compositions for treating hiv-associated diarrhea |
-
2013
- 2013-03-15 JP JP2015546448A patent/JP2016505561A/ja active Pending
- 2013-03-15 US US13/840,861 patent/US20140163096A1/en not_active Abandoned
- 2013-03-15 EP EP13860056.4A patent/EP2928560A4/en not_active Withdrawn
- 2013-03-15 MX MX2015007065A patent/MX2015007065A/es unknown
- 2013-03-15 CA CA2893070A patent/CA2893070A1/en not_active Abandoned
- 2013-03-15 WO PCT/US2013/032395 patent/WO2014088629A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505561A5 (enExample) | ||
| US9044479B2 (en) | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation | |
| JP2013540826A5 (enExample) | ||
| Thurman et al. | Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics | |
| JP6313413B2 (ja) | アナフィラキシーの処置におけるレボセチリジン及びモンテルカストの使用 | |
| Greer et al. | Pharmacokinetics of oseltamivir according to trimester of pregnancy | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2020522560A5 (enExample) | ||
| JP2016505561A (ja) | Ｈｉｖ関連下痢を治療する方法および組成物 | |
| Cui et al. | Caffeic acid phenethyl ester: an effective antiviral agent against porcine reproductive and Respiratory Syndrome Virus | |
| JP2013523628A5 (enExample) | ||
| CN103736030A (zh) | 治疗痛经的中药复方制剂及其制备方法和用途 | |
| US20210346402A1 (en) | Methods of treatment for disease from coronavirus exposure | |
| US20210361673A1 (en) | Compositions and methods of treating viral infections | |
| ES2678122T3 (es) | Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial | |
| White et al. | Effects of naproxcinod on blood pressure in patients with osteoarthritis | |
| Gunarathna et al. | Effect of Panchatikta Ghrita and Gandhakadi Taila in the Management of Kitibha (Psoriasis)-A Case study | |
| WO2021110737A1 (en) | Use of masitinib for the treatment of eosinophilic asthma | |
| JP2012102085A (ja) | Ｐｄｅ５阻害剤含有医薬組成物 | |
| US10213444B2 (en) | Composition and method for treating bipolar disorder | |
| KR102395041B1 (ko) | 수면, 사회적 상호 작용, 근심 또는 걱정의 개선을 위한 생약 방법 | |
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| CN117257790A (zh) | 芹菜素在制备用于治疗银屑病的药物中的应用 | |
| CN118078795A (zh) | 乙酸异丁香酚酯在制备预防和/或治疗炎症性肠病的药物中的用途 |